High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients
| Autor: | A. Migliore, Ida Pavese, G. Mancino, F. Satta, M. Di Palma, R. Borghesi, E. Brunetti, A. Alimonti, P. Piselli, P. Piergrossi, F. Todi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Cancer Fatigue Anemia Enzyme-Linked Immunosorbent Assay Gastroenterology chemistry.chemical_compound Hemoglobins Lactate dehydrogenase Internal medicine Neoplasms Antineoplastic Combined Chemotherapy Protocols medicine Humans Survival rate Erythropoietin Aged business.industry Interleukin-6 Tumor Necrosis Factor-alpha Case-control study Epoetin alfa Cancer Hematology Middle Aged medicine.disease Recombinant Proteins Epoetin Alfa Survival Rate Endocrinology Treatment Outcome Oncology chemistry Case-Control Studies Hematinics Female business medicine.drug |
| Zdroj: | BASE-Bielefeld Academic Search Engine |
| Popis: | A number of anaemic cancer patients are not responsive to treatment with recombinant human erythropoietin (rHuEPO). The aim of the present study is to investigate whether serum levels of tumour necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-6 and additional laboratory parameters, together with clinical variables, can predict the clinical outcome of treatment with rHuEPO in anaemic cancer patients.Thirty-five cancer patients and 25 healthy controls were enrolled in this study. Patients were treated with epoetin alfa at the dose of 150 IU/kg s.c. three times a week for 12 weeks. If the haemoglobin (Hb) level failed to improve at least 2 g/dl above baseline by week 6 of treatment, dose was increased to 300 IU/kg s.c. for the remainder of the treatment period. All patients filled out the Brief Fatigue Inventory (BFI), a questionnaire for the self-evaluation of cancer-related fatigue. Serum samples from patients and control groups were frozen at -80 degrees C and TNF-alpha, IL-1beta and IL-6 were later examined by enzyme-linked immunosorbent assay.Fatigued cancer patients had significant higher levels of circulating TNF-alpha, IL-1beta and IL-6 than healthy controls. Responders (Rs) to erythropoietin had significant lower medium levels of TNF-alpha and IL-6 than nonresponders (NRs). Fatigued patients with a general BFI scoreor =6 presented higher medium level of cytokines than nonfatigued patients (general BFI score6), but each group responded similarly to treatment with rHuEPO.High serum levels of TNF-alpha and IL-6 at the baseline are significantly correlated with a negative response to administration with rHuEPO. Thus, pretreatment evaluation of TNF-alpha and IL-6 serum levels can help to select those patients who are most likely to benefit from treatment with rHuEPO. On the contrary, Hb level, red blood cell count, lactate dehydrogenase and BFI score do not predict the outcome of treatment with rHuEPO. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|